TABLE 1.
Demographic results and linear measurements in radiographs of the included patients
| No. | Age/Sex | Site | PMH | Bone substitute | Membrane | Surgery type | Adverse reaction | Follow‐up period | Defect length | Defect height | Augmented height | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| After surgery | Last follow‐up | Change | |||||||||||
| 1 | 53/F | #37 | Mitral stenosis (anticoagulant medication) | DBBM | NCCM | First stage | ‐ | 7 years 6 months | 19.84 mm | 3.89 mm | 3.62 mm | 3.58 mm | −0.04 mm |
| 2 | 69/F | #17 | ‐ | DBBM | NCCM | Second stage | Wound dehiscence | 3 years | 18.65 mm | 5.27 mm | 4.55 mm | 4.42 mm | −0.13 mm |
| 3 | 43/F | #16, #17 | ‐ | DBBM | NCCM | First stage | ‐ | 5 years | 22.88 mm | 4.6 mm | 4.6 mm | 4.68 mm | 0.08 mm |
| 4 | 65/M | #26 | ‐ | DBBM | NCCM | First stage | ‐ | 6 years | 8.95 mm | 5.52 mm | 4.64 mm | 4.65 mm | 0.01 mm |
| 5 | 52/M | #47 | ‐ | DBBM | NCCM | Second stage | ‐ | 3 years | 16.5 mm | 6.66 mm | 7.48 mm | 6.02 mm | −1.46 mm |
| 6 | 59/M | #26 | Hypertension (anticoagulant medication) | DPBM | NCCM | Second stage | ‐ | 2 years 6 months | 11.77 mm | 9.76 mm | 10.67 mm | 9.92 mm | −0.75 mm |
| 7 | 60/M | #47 | ‐ | DPBM | NCCM | Second stage | ‐ | 2 years | 15.97 mm | 6.98 mm | 7.25 mm | 6.44 mm | −0.81 mm |
| 8 | 45/F | #16 | ‐ | DPBM | NCCM | Second stage | ‐ | 2 years | 15.59 mm | 5.06 mm | 4.99 mm | 4.35 mm | −0.64 mm |
| 9 | 71/F | #14, #15 | Osteoporosis (bisphosphonate medication) | DBBM | NCCM | Second stage | ‐ | 1 year 6 months | 12.23 mm | 6.35 mm | 5.78 mm | 4.94 mm | −0.84 mm |
| 10 a | 38/F | #27 | ‐ | DPBM | NCCM | Second stage | ‐ | 2 years | 14.38 mm | 5.38 mm | 5.08 mm | 5.48 mm | 0.4 mm |
| 11 | 69/M | #47 | ‐ | BCP | CCM | First stage | Delayed healing | 1 year 4 months | 12.34 mm | 7.83 mm | 6.71 mm | 6.64 mm | −0.07 mm |
| 12 | 68/F | #16, #17 |
Diabetes (controlled); Osteoporosis (bisphosphonate medication) |
DPBM | NCCM | First stage | Delayed healing | 1 year 3 months | 14.99 mm | 4.94 mm | 4.44 mm | 4.35 mm | −0.09 mm |
| 13 | 69/F | #16, #17 | Osteoporosis (Bisphosphonate medication) | DPBM | NCCM | Second stage | ‐ | 2 years | 22.93 mm | 7.6 mm | 6.89 mm | 6.06 mm | −0.83 mm |
| 14 | 49/F | #36 | Chondromalacia | DPBM | NCCM | Second stage | ‐ | 2 years | 12.12 mm | 10.48 mm | 10.53 mm | 8.57 mm | −1.96 mm |
| 15 | 63/M | #26, #27 | ‐ | DPBM | NCCM | Second stage | Wound dehiscence | 2 years | 23.26 mm | 7.51 mm | 11.03 mm | 6.33 mm | −4.7 mm |
| 16 | 57/M | #11 | Atrial fibrillation, pacemaker (anticoagulant medication) | DPBM | NCCM | First stage | ‐ | 1 year 6 months | 7.97 mm | 10.22 mm | 8.68 mm | 8.32 mm | −0.36 mm |
| 17 | 66/M | #24, #25 | Brain stent (Anticoagulant medication) | DPBM | NCCM | Second stage | Delayed healing | 1 year | 15.81 mm | 6.14 mm | 5.83 mm | 5.16 mm | −0.67 mm |
| 18 | 55/M | #25 | ‐ | DPBM | NCCM | Second stage | ‐ | 2 years | 10.34 mm | 7.16 mm | 8.02 mm | 7.08 mm | −0.94 mm |
| 19 | 66/M | #37 | ‐ | DPBM | NCCM | First stage | Delayed healing | 2 years | 9.65 mm | 4.91 mm | 4.17 mm | 3.94 mm | −0.23 mm |
| 20 | 66/F | #13–#16 | ‐ | DPBM | NCCM | Second stage | ‐ | 1 year 6 months | 35.37 mm | 5.91 mm | 4.94 mm | 5.24 mm | 0.3 mm |
| 21 | 52/M | #21 | ‐ | DBBM | NCCM | First stage | ‐ | 3 years | 6.51 mm | 8.54 mm | 7.08 mm | 7.6 mm | 0.52 mm |
| 22 | 43/F | #35–#37 | ‐ | DPBM | NCCM | Second stage | Delayed healing | 1 year | 28.69 mm | 8.45 mm | 5.48 mm | 3.37 mm | −2.11 mm |
| Average ± Standard deviation | 16.22 ± 7.06 | 6.78 ± 1.86 | 6.48 ± 2.19 | 5.78 ± 1.72 | −0.70 ± 1.13 | ||||||||
Abbreviations: BCP, biphasic calcium phosphate (Osteon II); CCM, cross‐linked collagen membrane (collagen membrane); DBBM, deproteinized bovine bone mineral (Bio‐Oss); DPBM, deproteinized porcine bone mineral (THE Graft); NCCM, non‐crosslinked collagen membrane (Bio‐Gide); PMH, past medical history.
a
One case showed early implant failure (3 months) of a transmucosally placed implant, but the replaced implant is in a clinically successful state thereafter.